Ratings by Oppenheimer (Francois Brisebois)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/21/2024 | DiaMedica Therapeutics Inc. | DMAC | Maintain | Outperform (N/A) |
|
Details | ||
| 3/15/2024 | Aquestive Therapeutics | AQST | Maintain | Outperform (N/A) |
|
Details | ||
| 3/7/2024 | MindMed | MNMD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/5/2024 | Dyne Therapeutics | DYN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/5/2024 | Avadel Pharmaceuticals | AVDL | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2024 | Tarsus Pharmaceuticals | TARS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/9/2024 | Avadel Pharmaceuticals | AVDL | Maintain | Outperform (N/A) |
|
Details | ||
| 1/3/2024 | Dyne Therapeutics | DYN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/12/2023 | Achieve Life Sciences | ACHV | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2023 | Achieve Life Sciences | ACHV | Maintain | Outperform (N/A) |
|
Details | ||
| 10/26/2023 | Simulations Plus | SLP | Maintain | Outperform (N/A) |
|
Details | ||
| 10/13/2023 | Ovid Therapeutics Inc | OVID | New Coverage | Outperform (N/A) |
3.61 (3.19) |
-11.63% | Details | |
| 8/17/2023 | MediWound Ltd | MDWD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2023 | Cybin Inc. | CYBN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/3/2023 | Cybin Inc. | CYBN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/30/2023 | Avadel Pharmaceuticals | AVDL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/26/2023 | Savara | SVRA | Maintain | Outperform (N/A) |
|
Details | ||
| 6/22/2023 | DiaMedica Therapeutics Inc. | DMAC | Upgrade | Outperform (Perform) |
3.64 (2.41) |
-33.79% | Details | |
| 6/21/2023 | Simulations Plus | SLP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/31/2023 | Aquestive Therapeutics | AQST | Maintain | Outperform (N/A) |
|
Details | ||
| 5/2/2023 | Avadel Pharmaceuticals | AVDL | Maintain | Outperform (N/A) |
|
Details | ||
| 4/3/2023 | icad Inc. | ICAD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/3/2023 | Processa Pharmaceuticals | PCSA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2023 | Avadel Pharmaceuticals | AVDL | Maintain | Outperform (N/A) |
|
Details | ||
| 2/15/2023 | Dyne Therapeutics | DYN | New Coverage | Outperform (N/A) |
13.32 (25.93) |
94.67% | Details | |
| 2/6/2023 | Bionano Genomics | BNGO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/10/2023 | Achieve Life Sciences | ACHV | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2022 | Compass Pathways | CMPS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/7/2022 | Durect Corp | DRRX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/30/2022 | MDxHealth SA | MDXH | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2022 | Avadel Pharmaceuticals | AVDL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/16/2022 | Cybin Inc. | CYBN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2022 | Achieve Life Sciences | ACHV | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2022 | Avadel Pharmaceuticals | AVDL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2022 | icad Inc. | ICAD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2022 | 9 Meter Biopharma | NMTR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2022 | 9 Meter Biopharma | NMTR | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2022 | Simulations Plus | SLP | Maintain | Outperform (N/A) |
|
Details | ||
| 10/13/2022 | Compass Pathways | CMPS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/3/2022 | Sensei Biotherapeutics | SNSE | Upgrade | Outperform (Perform) |
1.55 (1.07) |
-30.97% | Details | |
| 9/27/2022 | Aquestive Therapeutics | AQST | Maintain | Outperform (N/A) |
|
Details | ||
| 9/27/2022 | 9 Meter Biopharma | NMTR | Maintain | Outperform (N/A) |
|
Details | ||
| 9/15/2022 | Processa Pharmaceuticals | PCSA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/12/2022 | MindMed | MNMD | Maintain | Outperform (N/A) |
|
Details | ||
| 9/7/2022 | Aquestive Therapeutics | AQST | New Coverage | Outperform (N/A) |
1.31 (4.32) |
229.77% | Details | |
| 8/29/2022 | Sera Prognostics Inc | SERA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/29/2022 | MDxHealth SA | MDXH | Maintain | Outperform (N/A) |
|
Details | ||
| 8/26/2022 | MindMed | MNMD | New Coverage | Outperform (N/A) |
0.87 (9.06) |
941.38% | Details | |
| 8/25/2022 | MediWound Ltd | MDWD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/17/2022 | DermTech Inc. | DMTK | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2022 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Outperform (N/A) |
|
Details | ||
| 8/1/2022 | Otonomy | OTIC | Downgrade | Perform (Outperform) |
1.43 (0.08) |
-94.41% | Details | |
| 7/18/2022 | Sensei Biotherapeutics | SNSE | New Coverage | Perform (N/A) |
2.06 (1.55) |
-24.76% | Details | |
| 7/18/2022 | Sera Prognostics Inc | SERA | New Coverage | Outperform (N/A) |
1.71 (10.07) |
488.89% | Details | |
| 7/18/2022 | 9 Meter Biopharma | NMTR | New Coverage | Outperform (N/A) |
0.24 (0.07) |
-70.83% | Details | |
| 7/18/2022 | Molecular Templates | MTEM | New Coverage | Outperform (N/A) |
1.04 (1.53) |
47.12% | Details | |
| 7/18/2022 | MDxHealth SA | MDXH | New Coverage | Outperform (N/A) |
7.10 (2.40) |
-66.2% | Details | |
| 7/18/2022 | MediWound Ltd | MDWD | New Coverage | Outperform (N/A) |
1.77 (16.93) |
856.5% | Details | |
| 7/18/2022 | DermTech Inc. | DMTK | New Coverage | Outperform (N/A) |
6.31 (0.62) |
-90.17% | Details | |
| 7/18/2022 | Bionano Genomics | BNGO | New Coverage | Outperform (N/A) |
1.54 (0.78) |
-49.35% | Details | |
| 7/7/2022 | DiaMedica Therapeutics Inc. | DMAC | Downgrade | Perform (Outperform) |
2.02 (2.41) |
19.31% | Details | |
| 6/29/2022 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/2/2022 | Tarsus Pharmaceuticals | TARS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/27/2022 | Achieve Life Sciences | ACHV | Maintain | Outperform (N/A) |
|
Details | ||
| 4/14/2022 | Cybin Inc. | CYBN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2022 | Kala Pharmaceuticals | KALA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/18/2022 | DiaMedica Therapeutics Inc. | DMAC | Maintain | Outperform (N/A) |
|
Details | ||
| 2/3/2022 | Kala Pharmaceuticals | KALA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/27/2022 | Processa Pharmaceuticals | PCSA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/5/2022 | icad Inc. | ICAD | Maintain | Outperform (N/A) |
|
Details | ||
| 12/1/2021 | Harmony Biosciences Holdings Inc. | HRMY | New Coverage | Outperform (N/A) |
35.58 (29.58) |
-16.86% | Details | |
| 11/23/2021 | Tarsus Pharmaceuticals | TARS | New Coverage | Outperform (N/A) |
25.07 (33.85) |
35.02% | Details | |
| 11/12/2021 | DiaMedica Therapeutics Inc. | DMAC | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2021 | icad Inc. | ICAD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2021 | Compass Pathways | CMPS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2021 | Cybin Inc. | CYBN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2021 | Processa Pharmaceuticals | PCSA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2021 | Durect Corp | DRRX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2021 | Compass Pathways | CMPS | New Coverage | Outperform (N/A) |
39.52 (8.46) |
-78.59% | Details | |
| 10/22/2021 | Kala Pharmaceuticals | KALA | Maintain | Outperform (N/A) |
|
Details | ||
| 10/18/2021 | Avadel Pharmaceuticals | AVDL | Maintain | Outperform (N/A) |
|
Details | ||
| 10/5/2021 | Cybin Inc. | CYBN | New Coverage | Outperform (N/A) |
2.19 (0.36) |
-83.56% | Details | |
| 9/22/2021 | Aerie Pharma | AERI | Maintain | Outperform (N/A) |
|
Details | ||
| 8/30/2021 | icad Inc. | ICAD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2021 | DiaMedica Therapeutics Inc. | DMAC | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2021 | Kala Pharmaceuticals | KALA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2021 | Processa Pharmaceuticals | PCSA | New Coverage | Outperform (N/A) |
5.98 (1.60) |
-73.24% | Details | |
| 7/30/2021 | Durect Corp | DRRX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/13/2021 | Simulations Plus | SLP | Maintain | Outperform (N/A) |
|
Details | ||
| 6/23/2021 | Achieve Life Sciences | ACHV | New Coverage | Outperform (N/A) |
7.93 (4.50) |
-43.25% | Details | |
| 5/24/2021 | Savara | SVRA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/9/2021 | DiaMedica Therapeutics Inc. | DMAC | New Coverage | Outperform (N/A) |
9.35 (2.02) |
-78.4% | Details | |
| 4/6/2021 | icad Inc. | ICAD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/16/2021 | icad Inc. | ICAD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/15/2021 | Savara | SVRA | New Coverage | Outperform (N/A) |
1.57 (4.73) |
201.27% | Details | |
| 2/26/2021 | Aerie Pharma | AERI | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2021 | icad Inc. | ICAD | New Coverage | Outperform (N/A) |
18.06 (1.51) |
-91.64% | Details | |
| 2/22/2021 | Otonomy | OTIC | Maintain | Outperform (N/A) |
|
Details | ||
| 2/2/2021 | Durect Corp | DRRX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/14/2021 | Flexion Therapeutics | FLXN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2021 | Simulations Plus | SLP | Maintain | Outperform (N/A) |
|
Details | ||
| 12/18/2020 | Otonomy | OTIC | Maintain | Outperform (N/A) |
|
Details | ||
| 11/23/2020 | Otonomy | OTIC | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2020 | Kala Pharmaceuticals | KALA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/8/2020 | Simulations Plus | SLP | New Coverage | Outperform (N/A) |
59.97 (45.91) |
-23.45% | Details | |
| 8/7/2020 | Pfenex Inc. | PFNX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/31/2020 | Avadel Pharmaceuticals | AVDL | New Coverage | Outperform (N/A) |
8.20 (17.92) |
118.54% | Details | |
| 7/31/2020 | Durect Corp | DRRX | New Coverage | Outperform (N/A) |
1.97 (0.82) |
-58.38% | Details | |
| 7/31/2020 | Flexion Therapeutics | FLXN | New Coverage | Outperform (N/A) |
13.52 (9.12) |
-32.54% | Details | |
| 7/7/2020 | Otonomy | OTIC | Maintain | Outperform (N/A) |
|
Details | ||
| 6/23/2020 | Pfenex Inc. | PFNX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/15/2020 | Pfenex Inc. | PFNX | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/1/2020 | Pfenex Inc. | PFNX | New Coverage | Outperform (N/A) |
7.31 (12.75) |
74.42% | Details | |
| 6/1/2020 | Otonomy | OTIC | New Coverage | Outperform (N/A) |
2.56 (0.08) |
-96.88% | Details | |
| 6/1/2020 | Aerie Pharma | AERI | New Coverage | Outperform (N/A) |
14.03 (15.25) |
8.7% | Details |
